Majority of Physicians Using Herceptin as Key Therapy for Gastric Cancer, But Satisfaction With Treatment Options Remains Low, According to Oncology Tracking Study by GfK HealthCare

BASEL, Switzerland--(BUSINESS WIRE)--In just over a month following the FDA’s October 2010 approval of Roche’s Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare. However, the research study also shows that physicians are not truly satisfied with current treatment options for gastric cancer, including Herceptin.